According to the Medicine Intelligence Data Investment Pattern Database, Yangqi Medical Chip, committed to becoming a pioneer in precision nuclear medicine, recently announced the completion of tens of millions of yuan in PreA round financing. This round of financing is led by Anfeng Venture Capital, and the raised funds will mainly be used for market promotion of approved products, approval of new product research and development, and expansion of the pet radiotherapy market.

Yangqi Medical Core was established in 2021, and its core founding team is composed of clinical experts in nuclear medicine, nuclear physics and artificial intelligence, tumor radiotherapy, and radiation physics from Stanford, Alibaba, and other domestic and foreign institutions. The company is headquartered in Shenzhen and has research and development centers in Hangzhou and Shanghai.

It is reported that Yangqi Medical Core is deeply involved in the fields of nuclear medicine and tumor radiation therapy. In response to clinical pain points during radiotherapy surgery, it uses a combination of software and hardware to give medical equipment smart eyes and brains, accurately control equipment operation and treatment, improve treatment effectiveness, and optimize patient experience. Since its establishment, Yangqi Medical Chip has completed 5 rounds of financing.

Yangqi Medical Core's products mainly focus on the field of optical surface guided radiotherapy (SGRT), including the optical surface monitoring product "Qishi", low-dose CT enhancement product "Light Shadow", and SRT low-energy superficial radiotherapy equipment.

Among them, "Qishi" is a non-invasive and radiation free image guidance technology. It obtains the patient's position in real-time through three-dimensional surface imaging and models the patient's surface with an accuracy of up to 0.2mm. This system can assist doctors in real-time judging the treatment effect based on the changes in posture and position of different patients during the treatment process, similar to "respiratory gating", achieving precise monitoring during the treatment process. Through high-precision real-time six degree of freedom registration, "Qishi" can effectively correct positioning errors and accurately guide the entire radiotherapy process.

Moreover, "Qishi" can also be widely used in a variety of clinical scenarios, such as deep inspiration breath holding (DIBH) for breast cancer, stereotactic radiotherapy (SRS) for brain tumors, stereotactic radiotherapy (SBRT) for liver cancer, cervical cancer, prostate cancer and other body tumors. It has a high-precision real-time monitoring function, which can effectively shorten the treatment time, reduce the radiation dose of normal tissues, and provide safer treatment plans for children, the elderly and other special patients.

Light Shadow "is an innovative CI image enhancement product that solves the problem of blurry and difficult to diagnose images in traditional low-dose CI mode. Through light imaging, the same imaging level can still be maintained even at the original 1/4 dose. Qingying also provides flexible deployment methods, suitable for various application scenarios; Provide structured data services to provide a secure and reliable data processing environment for medical devices, and cooperate with privacy multi-party secure computing to provide guarantees for device data fusion.

In addition, Yangqi Medical Chip is also entering the pet market. According to the White Paper on China's Pet Industry from 2023 to 2024, the number of pet dogs in China will be 51.75 million, a year-on-year increase of 1.1%, and the number of pet cats will be 69.8 million, a year-on-year increase of 6.8%, making it the second largest pet market in the world. And, according to a recent report released by Goldman Sachs, the number of pets in China has exceeded the number of infants and young children under the age of 4 for the first time this year, and it is expected that by 2030, the number of pets will be close to twice the number of infants and young children.

The significant increase in the number of pets also represents a sharp rise in the pet market share. During the in-depth investigation of superficial radiotherapy, Yangqi Medical Xin unexpectedly discovered that pets can also suffer from tumors and skin diseases. Therefore, the pet version of the shallow radiation therapy equipment developed by Yangqi Medical Core not only has the ability to treat skin diseases, but also adds intraoperative radiation therapy function, that is, simultaneous radiation therapy during the surgical process. In addition, pet radiotherapy equipment is designed and designed to better suit the characteristics of small animals in terms of appearance and function. It is equipped with a professional pet version treatment head to adapt to the body size of small animals, and natural cavities and other treatment methods are added to meet different treatment needs.

Next, Yangqi Medical Chip will increase its efforts in market commercialization. On the one hand, we will engage in deep clinical cooperation with top hospitals to create exemplary benchmarks; On the other hand, we will work together with agents nationwide to expand the market; In addition, the company will actively seek ecological cooperation with domestic and foreign radiotherapy equipment manufacturers to seek common development. In the field of pet healthcare, the company has reached cooperation with some top pet hospitals in order to explore industry guidance standards for superficial radiotherapy of pet tumors and become a pioneer in this field.

Regarding obtaining this round of financing, Tianyuan, co-founder of Yangqi Medical Chip, stated that since its establishment in 2021, Yangqi Medical Chip has always focused on the fields of nuclear medicine and tumor radiation therapy, and has received support from multiple rounds of capital from new and old shareholders. At present, the company has gradually entered the stage of commercial market development from the product research and development phase, and the soon to be certified products have also been fully validated in clinical practice. Yangqi will gradually achieve large-scale sales and plan to steadily expand its product line by 2025, accelerate the research and development of new products, and continue to polish the products needed in clinical and market applications. At the same time, Yangqi will increase market investment and provide precise and intelligent product solutions for more clinical radiotherapy scenarios.

Source: https://news.yaozh.com/archive/44558.html